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Although recent FDA approvals on ipilimumab and sipuleucel-T represent major milestones, the ultimate success of
immunotherapy approaches will likely benefit from appropriate combinations with other immunotherapeutic and/or
non-immunotherapeutic approaches. However, implementation of ideal combinations in the clinic may still face
formidable challenges in regulatory, drug-availability and intellectual property aspects. The 2011 SITC annual
meeting hosted a workshop on combination immunotherapy to discuss: 1) the most promising combinations
found in the laboratory; 2) early success of combination immunotherapy in clinical trials; 3) industry perspectives on
combination approaches, and 4) relevant regulatory issues. The integrated theme was how to accelerate the
implementation of efficacious combined immunotherapies for cancer patients. Rodent animal models are providing
many examples of synergistic combinations that typically include more than two agents. However, mouse and
human immunology differ in a significant number of mechanisms and hence we might be missing opportunities
peculiar to humans. Nonetheless, incisive animal experimentation with deep mechanistic insight remains the best
compass that we can use to guide our paths in combinatorial immunotherapy. Combination immunotherapy
clinical trials are already in progress and preliminary results are extremely promising. As a key to translate promising
combinations into clinic, real and “perceived” business and regulatory hurdles were debated. A formidable step
forward would be to be able to test combinations of investigational agents prior to individual approval. Taking
together the FDA and the industrial perspective on combinatorial immunotherapy, the audience was left with the
clear message that this is by no means an impossible task. The general perception is that the road ahead of us is
full of combination clinical trials which hopefully will bring clinical benefit to our cancer patients at a fast pace.
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Anti-PD/PD-L1The need for immunotherapy combinations
The long quest to attain clinical benefit in cancer
patients by activating the immune system against such a
deadly disease is finally paying off [1,2]. Exciting results
have been recently reported with immunostimulatory
monoclonal antibodies (mAbs) [3–6], with cancer vac-
cines [7] and with adoptive T cell therapies [8,9]. Success
and optimistic perspectives have brought steadily in-
creasing industrial interest in this area of research. At
this point in time the private and public sectors are* Correspondence: imelero@unav.es
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distribution, and reproduction in any mediummoving the field of immunotherapy forward at an unpre-
cedented pace.
An important lesson to be learned from past major
victories against human diseases is that combined treat-
ments are often the key to synergistically achieve clinical
success. Let us consider for instance antibiotic combina-
tions for Mycobacterium tuberculosis [10], combined
chemotherapies for pediatric acute lymphoid leukemias
[11] or HAART for AIDS patients [12]. It is unlikely that
individual immunotherapeutic agents, even considering
the most efficacious examples of them, will be ultimately
successful as monotherapy. In fact abundant data in
mouse models provide very solid evidence for examplesCentral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Such preclinical examples of synergistic combinations in-
clude combinations of multiple immunotherapeutic
agents and combinations of immunotherapies with other
modalities of cancer treatment. These combinations will
be required because of multiple resistance mechanisms
that tumors utilize to evade immune responses as well as
the numerous mechanisms that normally limit host im-
mune responses in health and disease. The wealth of
knowledge about tumor evasion of immune rejection to-
gether with preclinical testing should hasten a number of
initiatives to explore combinations in the clinical arena.
The following four themes were selected for the focus
of a workshop at the 2011 SITC meeting devoted to im-
munotherapy using combinatorial treatment approaches:
(i) How to best identify at an early stage of development
the most efficacious combinations; (ii) How to recognize
problems of safety early in development; (iii) How to ap-
proach combinatorial treatments from a regulatory point
of view; and (iv) How to deal with legitimate interests of
intellectual/industrial property, commercialization and
risk-taking in the life-cycle of innovative drugs. Authori-
tative speakers addressed these points and the sessions
were designed with ample discussion time to facilitate
dialogue among participants with a diverse range of ex-
pertise and experience.
Palettes of immunotherapy agents to be
combined
As a result of decades of investigation we have acquired
clinical evidence for the therapeutic activity of a number of
immunotherapy agents that now become the focus of po-
tential combinatorial therapies. The palette of immuno-
therapies includes enhancers of dendritic cell function,
vaccines, adoptive T cell transfer including genetically
modified T cells, immune checkpoint inhibitors and agents
to neutralize or inhibit suppressive cells, and cytokines.
The therapeutic immune response against tumors involves
different layers that are to be tampered with in order to or-
chestrate a clinically meaningful outcome. As shown in
Figure 1, these include factors modulating innate immun-
ity, modulation of T cell activation and inhibition, factors
modifying the tumor microenvironment, and means to
provide or attain antigen priming or boosting. The abun-
dance of promising products raises the following crucial
question: Which agents warrant focused funding for clin-
ical development? [17] Their potential for rational combi-
nations among them should be a major guidance factor for
selection.
Kim Margolin (University of Washington) reported the
coordinated efforts of the Cancer Immunotherapy Trials
Network (CITN) to build upon the collective experience
and accumulated wisdom of “the field” to prioritize drugs,
regimens and most importantly to conduct combinationtrials with high priority agents. In a series of workshops pro-
moted by the NCI with broad scientific input, IL-15, anti-
CD40, anti-PD-1, and IL-7 were defined as the most com-
pelling for providing patient benefit in the near term. Of
note, anti-CTLA-4 mAbs were excluded from discussion
since ipilimumab had already been submitted for FDA
approval.
IL-15 is a cytokine that increases CD8 and NK cells
both in numbers and activity [18]. A phase I clinical trial
using recombinant IL-15 includes an escalation dose of
rhIL15 (0.50, 1.0, 2.0 and 3.0 mcg/kg/day) in patients
with melanoma, renal and colon cancer (NCT01021059).
The primary aim is to select outpatient doses and sche-
dules to safely enhance various T-cell (CAR, vaccines)
and NK cell (ADCC) therapies An extensive immune
monitoring protocol will also be performed. Preliminary
results presented at the SITC meeting from the first-in-
human clinical trial (Tom Waldmann, NCI) suggest that
humans are more sensitive than primates to intravenous
recombinant IL-15 and at least in bolus infusion there
were unexpected signs of acute toxicity at low doses in-
cluding severe hypotension and high fever. Continuous
infusion may be a way to overcome this problem, and
subcutaneous administration is being considered.
IL-7 is a homeostatic growth factor for T cells. IL-7 is
well tolerated in humans in a broad dose range
(3–60 μg/kg/dose) and has been tested in patients with
advanced cancers [19]. It increases the number of circu-
lating CD4 and CD8 T cells and promotes spleen and
lymph node enlargement [20]. IL-7 preferentially
expands naïve T cells while reducing Treg numbers and
function. CITN is proposing three clinical trials combin-
ing IL-7 with vaccines in prostate cancer (Sipuleucel
T-Dendreon), melanoma (MAGE3 protein - GSK) and
chimeric antigen receptor transfected T cells in ovarian
cancer (CARs).
Vaccines
Malignant tumors display a multitude of genetic abnor-
malities that can generate tumor specific antigens (TSAs)
recognizable by the immune system. Dendritic cells can
take-up TSAs and depending on the environmental con-
ditions, present the antigens in the tumor microenviron-
ment or at lymphoid organs to mount, sustain or
abrogate the antitumor immune response. Cancer vac-
cines try to exploit these mechanisms by using potent
antigens combined with the appropriate danger signals to
initiate and maintain an antitumoral response. One of the
most extensively studied tumor antigens is the tumor
specific idiotype present in B cell lymphomas. Larry Kwak
(M.D. Anderson Cancer Center) discussed his experience
with anti-idiotype cancer vaccines in follicular lymph-
oma. The tested products are composed of tumor-derived
Ig-containing tumor specific idiotypic determinants. The
Figure 1 SITC meeting overview of cancer immunotherapy and potential combination strategies within four key categories: Innate
immunity, T cell activation, Tumor micro-environment, immune priming and boosting. Treatments are grouped in categories according to
mechanism of action. Some of the listed products intervene in more than one category. A rational for combinations with elements taken from
each of the different mechanistic categories should lead to optimized efficacy, while maybe minimizing autoimmune adverse effects.
(CTX = cyclophosphamide, ARA= arabinoside, GEM=gemcitabine).
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which serves as a carrier protein and an immune stimu-
lant. The vaccine is injected with GM-CSF used as an ad-
juvant to attract and differentiate dendritic cells at the
site of subcutaneous vaccination. In a Phase II clinical
trial the majority of patients mounted specific CD8+ T
cell responses against the idiotype [21]. About half of the
subjects are still in remission (>10 years) and never have
received Rituximab. These positive results paved the way
for the design of a Phase III clinical trial. Patients with
follicular lymphoma were randomized after complete re-
mission to receive the full vaccine or the components of
the vaccine without the specific Ig. In a modified intent
to treat analysis the vaccine prolonged disease-free sur-
vival. A subset analysis revealed that IgM isotype lymph-
omas have a better response to the vaccine when
compared to lymphomas of IgG isotype [22].
When these idiotype vaccine trials were started, rituxi-
mab (anti-CD20, now a standard of care in lymphoma)
had not been approved yet. In a trial involving mantle
cell lymphoma patients, vaccination was administered
after remission induction with six cycles of EPOCH
chemotherapy plus rituximab. Median overall survival of
8.7 years compared very favorably with historical con-
trols in which the expected survival is about 3–4 years.
This is important because depletion of normal B by the
anti-CD20 mAb cells does not seem to counteract the
benefit of vaccination [23].
Hormone refractory prostate cancer is a very suitable
therapeutic target for development of a cancer vaccineapproach. In this disease there is a long interval from
primary diagnosis to metastatic disease and serum PSA
(doubling time velocity) can be used as a surrogate mar-
ker for therapeutic response or disease recurrence. Re-
cently, Sipuleucel-T (a product containing PBMC pulsed
with a fusion protein of prostatic acid phosphatase (PAP)
with GMSF) has been approved as a first line treatment
in castrate resistant metastatic prostate cancer. This au-
tologous cellular product, derived from sequential leuka-
phereses, is complex and may combine the effects of
vaccinating against PAP and adoptive transfer of primed
T cells in subsequent infusions [24]. Additional prostate
cancer vaccine strategies with the injection of viral vec-
tors are currently in clinical trials. Philip Arlen (National
Cancer Institute) described the experience with Prostvac,
a viral vector encoding transgenes for PSA as a tissue
restricted antigen, and three immune costimulatory
molecules (B7.1, ICAM-1, and LFA-3). A Phase II clin-
ical trial reported an 8.5-month improvement of overall
survival in patients with prostate cancer [25]. Combina-
tions of vaccines with chemotherapy, radiotherapy and
hormone blocking therapy are expected. A randomized
trial is ongoing for patients with nonmetastatic CRPC re-
ceiving vaccine (rV-PSA/B7.1, rF-PSA) or androgen re-
ceptor antagonist (Nilutamide) with crossover at
progression. It is very enticing to observe that there was
a 59% survival in patients receiving the vaccine first
compared to 39% of those patients that receive niluta-
mide before progression [26]. Vaccination requires in
some instances a long period of time to observe clinical
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use vaccines after progression in CRPC.
Monoclonal antibodies modulating the immune
system
T cells require different signals for appropriate expansion
and acquisition tumoricidal functions [27]. Signal 1 is
initiated after cognate T-cell receptor binding to a MHC-
peptide complex on the surface of an antigen-presenting
cell. Co-regulatory molecules including CD28 and
CTLA-4 that bind to CD80 and CD86 deliver or modu-
late signal 2. Moreover, other co-regulatory interactions
and paracrine cytokines, both stimulatory and inhibitory,
shape and direct the type of response (signal 3). Crucially,
negative regulators modulate the grade of T cell activa-
tion and protect the organism from deleterious effects
mediated by uncontrolled T cell activation. CTLA-4 is
one of these co-inihibitory molecules expressed on acti-
vated T cells. It binds CD80 and CD86 with an affinity at
least 100-fold higher than CD28. A fully human mAb
blocking this interaction has been approved for the treat-
ment of metastatic melanoma [5,6].
PD-1 is a co-inhibitory receptor that shows homology
with CD28 and whose expression is induced following
activation on CD4+ and CD8+ T cells as well as on other
immune cells. Its cognate ligands are the members of the
B7 family PD-L1 (B7-H1) and PD-L2 (B7-DC). PD-1
triggering on the T cell leads to a non pro-apoptotic in-
hibition of T cell proliferation and activation dependent
on recruitment of a tyrosine phosphatase that represses
signaling at immune synapses [28]. In animal models of
infectious disease, PD-1 is upregulated in both acute and
chronic LCMV infection but stays high in chronic infec-
tion marking exhausted T cells. Indeed, PD-1 is consid-
ered as a decisive exhaustion marker along with LAG-3,
CD160, BTLA, and 2B4. Three antibodies against PD-1
have started clinical trials in patients with advanced can-
cers. Early reports suggest excellent clinical activity with
conspicuously long-lasting responses and disease
stabilization [2,29]. In addition there is interest in select-
ively modulating PDL1 given other inhibitory interac-
tions of this molecule [30] and the anti-apoptotic signals
of PDL1 to tumor cells [31].
HVEM is a member of the TNFR superfamily with
multiple ligands, both stimulatory and inhibitory. Gor-
don Freeman’s group (Dana Farber Cancer Institute) has
demonstrated that deletion of HVEM cysteine rich do-
main 1 (CRD1) interferes with the binding capacity of
the inhibitory receptors BTLA and CD160. In contrast,
HVEM lacking CRD1 is a stimulatory receptor through
interactions with LIGHT. B16 melanoma expressing
HΔD1 (HVEM with deletion of CRD1 domain) becomes
immunogenic and mice harboring irradiated B16-HΔD1
survive longer compared to B16 recipient mice. Treatmentefficacy is further improved with the concomitant use of
anti-CTLA4 and anti-PD-1 mAbs. The combined strategy
greatly enhances lymphocyte trafficking into tumor sites.
Optimal immunotherapy may involve a combination of
blockade of inhibitory signals and provision of costimula-
tory signals as if releasing the brakes and stepping on the
gas pedal of a car [3]. The above strategy may be used to
endow cellular vaccines with immune stimulating proper-
ties, through genetically introduced expression of molecules
such as GM-CSF, Flt-3-ligand, ICOS-ligand and others
[32,33].
CD40 is a costimulatory molecule expressed on antigen
presenting cells and frequently on neoplastic cells with no
intrinsic kinase activity. CD40-CD40L interactions facilitate
dendritic cells (DCs) to increase expression of CD80 and
CD86 and threby activate T cells. A fully human mAb
(CP-870,893) that recognizes CD40 has been developed and
shown to activate human DCs. This mAb is currently in
clinical trials for several types of malignant tumors. Robert
Vonderheide (University of Pennsylvania) described his
experience with anti-CD40 mAb in pancreatic cancer [34].
Agonist CD40 mAb combined with gemcitabine induced
major clinical remissions in patients with pancreatic
adenocarcinoma. CD40-dependent treatment effects can
be reproduced in a genetically engineered mouse model of
the disease. Strikingly, the therapeutic mechanism fol-
lowing CD40 activation is not T cell-dependent, but rather
is macrophage-dependent. Intriguingly, CD40-activated
macrophages rapidly infiltrate and kill tumor cells, and
facilitate depletion of tumor stroma. CD40 can work
effectively to induce tumor infiltrating T cells but
requires gemcitabine for antigen priming outside the
tumor microenvironment.
Monoclonal antibodies that bind stimulatory or inhibi-
tory receptors are excellent pharmacological tools to
magnify the role of receptor-ligand pairs in cancer im-
munotherapy. However, there are some unknowns about
mechanisms underlying the action of these mAbs. Martin
Glennie (University of Southampton) discussed the physi-
ology of Fc receptors and effects on the function of anti-
CD40 mAb [35]. This British group concomitantly with
Li and Ravetch [36] at Rockefeller University (NYC)
found that the isotype of the mAb plays a crucial role in
the activity of anti-CD40 mAb. IgG1 is optimal in mouse
models due to its ability to bind FcγRIIB in vivo, thereby
allowing cross-linking of the FcR receptor upon cell-
to-cell contact with the responding leukocytes. Early results
from the same group suggest that other immunostimula-
tory mAbs are FcR cross-linking dependent. Understand-
ing these mechanisms will allow fine-tuning of agonistic
mAbs and may optimize the benefit:toxicity ratio of these
agents.
The immune system recognizes CpG oligonucleotides
through TLR9 receptors that activate B-lymphocytes and
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apy promotes systemic lymphoma eradication in mice
[37] with interesting results in humans [38]. CpG in situ
vaccination induces anti-tumor T cells that express
CD45RO and CD137. This type of treatment is practical
(no need for a customized product), safe and repeatable.
The group of Ron Levy (Stanford University) identified
combinations with immunostimulatory mAbs that ex-
tend the efficacy of CpG intratumoral injections in mur-
ine models. In transplanted tumors, OX40 and CTLA4
were highly expressed on tumor-infiltrating lymphocytes
compared to T cells in the spleen or draining lymph
nodes. Most OX40/CTLA4+ T cells infiltrating tumors
were FOXP3+ regulatory T cells. When mice were intratu-
morally treated with anti-OX40 and anti-CTLA4 mAbs,
FOXP3+CD4+ T cells were depleted and established
tumors eliminated using as low as 1/100 of the needed dose
when given systemically. This intratumoral route was also
capable of inducing the rejection CNS leukemia metastases.
The message is: “treat locally, cure systemically”.
Opportunities for synergy with non-immune
therapies
Vemurafenib is a BRAF inhibitor that improves overall
and progression-free survival in metastatic melanoma
patients. Vemurafenib selectively blocks the aberrant
serine/threonine kinase activity arising from the com-
mon BRAF V600E mutation in melanoma cells. The
good news is that this drug does not eliminate immune
cells and does not interfere with MAPK signaling in T
lymphocytes. In fact, vemurafenib has been reported as
an immunosensitizer because it increases the availability
of tumor antigens and seems to stimulate NK activating
receptors. Synergy with immunotherapy is at least theor-
etically expected. The group of Antoni Ribas (University
of California Los Angeles) has generated a murine mel-
anoma line, SM1, harboring BRAF V600E. SM1 cells are
moderately sensitive to vemurafenib and were trans-
fected with chicken ovalbumin as a model antigen. BRAF
inhibitors do not change gp100 melanoma antigen ex-
pression in SM1 cells. In combination therapy experi-
ments with adoptive T cell transfer (OT-1 T cells or
Pmel TCR-transgenic lymphocytes) vemurafenib is
highly efficacious in mice bearing these tumors. This
compound does not increase T cell homing to tumors
but enhances cytokine production by tumor infiltrating
lymphocytes. A phase I/II clinical trial combining vemur-
afenib and ipilimumab in metastatic melanoma is cur-
rently recruiting patients (NCT01400451).
Chemotherapy is one of the pillars of conventional
cancer treatment. During the last few years the group of
Laurence Zitvogel and Guido Kroemer in Paris has pos-
tulated and defined a key role for the immune system in
the mechanisms of action of chemotherapy. In particularsome drugs such as anthracyclines and oxaliplatin re-
quire a functional immune system to exert therapeutic
effects [39]. Immunogenic cell death is accomplished by
a complex molecular machinery that ultimately exposes
calreticulin at the cell surface of cancer cells, as well as ATP
and HMGB1 release. In a recent series of experiments using
tumor cells deficient for ATG5 or ATG7, Zitvogel et al
demonstrated that autophagy is essential for immunogenic
cell death [40].
As an important corollary for those chemotherapeutic
agents that do not induce immunogenic cell death, an
additional drug can take over the activation of the miss-
ing hallmark of immunogenic cell death. An extensive
screening by Zitvogel’s group has discovered a previously
undescribed role for digoxin in cancer. Cardiac glyco-
sides in mice promote immunogenic cell death when
combined with non-immunogenic chemotherapeutic
drugs such as mitomycin-C. Interestingly, in a retro-
spective analysis, cancer patients receiving concomitantly
chemotherapy and digoxin exhibited improved overall
survival when compared to patients who were not on di-
goxin. This effect was restricted to select tumor types in-
cluding breast cancer, colorectal cancer, hepatocellular
carcinoma, head and neck cancer but not prostate or
lung cancer (Zitvogel et al unpublished data).
Malignant cells require new blood vessels to grow. The
major proangiogenic factor VEGF can also contribute to
the immunosuppressive environment found in cancer
tissues [41]. Monoclonal antibodies that inhibit VEGF
(i.e. bevacizumab) are used to treat cancer patients and
can enhance the number of activated DCs and impair
the function of regulatory T cells [42].
During the clinical testing of ipilimumab, Stephen
Hodi (Dana Farber Cancer Institute) observed that this
anti-CTLA-4 mAb induced hemorrhagic necrosis and
immune mediated vasculopathy [43]. Ipilimumab also
promotes the development of antibodies to VEGF-A in
long-term surviving melanoma patients [44]. In addition
VEGF may drive immunosuppressive loops. Therefore,
anti-CTLA4 mAb might synergize with anti-VEGF anti-
bodies. To test this hypothesis, Dr. Hodi designed a
Phase I clinical trial for the combination of ipilimumab
and bevacizumab in melanoma patients. Post-treatment
biopsies demonstrated morphologic changes in tumor
blood vessels and extensive immune effector cell traffick-
ing. In peripheral blood a consistent increase in both
CD4 and CD8 memory T cells was observed. This com-
bination trial is still in progress (NCT00790010) with
promising results in terms of clinical activity and safety
in melanoma patients. At the end of his talk, Dr. Hodi
commented on his three-year ordeal to (i) secure cooper-
ation between the two companies owning the drugs, (ii)
obtaining funds for the trial and (iii) the process of get-
ting the regulatory approval of the trial by the FDA.
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cooperative development of combination
therapies
Combination immunotherapy in cancer often requires
navigating through multiple layers of regulatory and
business challenges. Raj K. Puri (Division of Cellular and
Gene Therapies, Office of Cellular, Tissue, and Gene
Therapies/CBER/FDA) discussed clear definitions and
information resources about combination products and
combinatorial therapies. A combination is composed
of two or more therapeutic components (drug, device,
or biological product) required for an intended effect
(i.e. mAb combined with a therapeutic drug). A combina-
torial product is a therapy combining multiple compo-
nents. The revision process for safety and efficacy of a
combination product is assigned to a FDA division accord-
ing to the primary mode of action (CBER for biologics,
CDER for drugs, CDRH for device) with consultancy from
the Office of Combination Product. The FDA provides on-
line resources for clarification (http://www.fda.gov/Bio
logicsBloodVaccines/NewsEvents/ucm232821.htm).
There are important ongoing efforts to coordinate IND
management without revealing trade secrets, and to co-
ordinate the FDA with regulatory organizations in Eur-
ope and Asia. These steps should simplify the required
evaluation processes and focus on safety.
Pharmaceutical companies could be reluctant to par-
ticipate in combination trials when their agent is still
under development as a monotherapy. David Bonk
(Bristol Myers Squibb) described legal and logistical
issues in the clinical evaluation of cancer immunotherapy
combinations. Legal barriers come in different flavors
(intellectual property, contracts, antitrust law, product
liability) but in actuality, he argued, there are very few true
legal obstacles. However, as expressed by Dr Bonk “there
are transactional dynamics that are sometimes expressed
in legal terms”. In his experience the most common
themes are failure to grasp the key interests and concerns
of the other negotiating partner and the desire of one party
to extract more value from the partnership than is
warranted by its own contribution or assets. It is important
to keep in mind the patients that could benefit for the use
of the combination.
Conclusions
Comments from audience comments reflected the ex-
citement of the different stake holders. Importantly, se-
nior management at leading pharmaceutical companies
is increasingly convinced of the translational value of
these therapeutic combinations. The many difficulties
are clearly perceived but there is also optimism in terms
of foreseeing unprecedented efficacy.
We are at the dawn of a new and exciting era: the art
and science of combinatorial immunotherapy will keepmany of us busy for years to come. This is no longer a
quixotic task, but a time of opportunity. Clinical transla-
tion in this new front in the war against cancer should
be given the highest priority and facilitated by regulatory
bodies. Drug companies, basic scientists and clinical
investigators are coming together. An army of visionaries
will be needed to succeed in the war against cancer.
SITC will provide the environment to assemble such an
army into the future.
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